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SUMMARY 
This thesis has been worked out in The laboratory for study of mitochondrial 
disorders (Departement of Pediatrics, 1st Faculty of Medcine, Chales university in Prague) 
and in cooperation with The Institute of Inherited Metabolic Disorders. 
Mitochondrial disorders represent a heterogeneous group of diseases with the onset 
at any age from neonatal period till adulthood, mostly presented with very severe clinical 
courses of disease. The mammalian organism is fully dependent on mitochondrial 
oxidative phosphorylation system as on the major energy producer of the cell. Therefore 
the mitochondrial disorders affect mainly high energy demanded tissues such as brain, 
heart or muscle. Simillar phenotype is observed in many lysosomal storage disorders. 
Despite of expanding knowledge of molecular basis of mitochondrial and 
lysosomal disorders, it may be still difficult to explain the exact pathogenesis of disease as 
well as the prognosis for patients and their families. 
 Mitochondrial functions affect more than just energy production; they contribute 
in initiation of apoptosis, in cellular calcium homeostasis, and in production of reactive 
oxygene species. Disturbed mitochondria become a goal of autophagy mediated by the  
lysosomal compartement. 
 
The results of our study enable: 
 
1. better understanding of the tissue specific impact of selected mtDNA mutations on 
the mitochondrial function in autoptic tissues 
 
2. better understanding of the relations between mitochondrial ultrastructure and 
functions in selected mitochondrial and lysosomal storage disorders on level of 
cultured fibroblasts. 
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SOUHRN 
 
Disertační práce byla vypracována v Laboratoři pro studium mitochondriálních 
poruch, Kliniky dětského a dorostového lékařství, 1. LF UK v Praze a ve spolupráci s 
Ústavem dědičných metabolických poruch, 1. LF UK v Praze. 
Práce vychází z dlouhodobého zaměření pracoviště na studium mitochondriálních 
onemocnění a spojuje problematiku primárně mitochondriálních onemocnění a sekundárních 
mitochondriálních  poruch  u vybraných  lysosomálních střádacích onemocnění.  
Mitochondriální onemocnění představují skupinu závažných onemocnění s nástupem 
od novorozeneckého věku až do dospělosti a u většiny pacientů mají velmi vážný průběh. 
Mitochondrie jsou hlavním producentem energie v savčí buňce a poruchy systému OXPHOS 
mají zásadní dopady především na tkáně s vysokou energetickou náročností. Obdobný 
fenotyp je společný i pro řadu lysosomálních střádacích onemocnění.  
I při známé molekulární podstatě mitochondriálních i lysosomálních onemocnění je 
stále obtížné odhadnout klinický průběh onemocnění i prognózu. 
Funkce mitochondrií se neomezuje pouze na produkci energie, ale hraje i významnou 
úlohu ve spouštění apoptózy, v produkci volných radikálů, je významným místem 
vápníkového metabolismu a poškozené mitochondrie se stávají cílem autofagie kontrolované 
lysosomy.  
 
Naše výsledky umožňují: 
 
1. lépe porozumět tkáňově specifickému dopadu vybraných mtDNA mutací na funkce 
mitochondrií v autoptických tkáních 
 
2. lépe porozumět souvislostem mezi mitochondriální ultrastrukturou a funkcemi u 
vybraných mitochondriálních a lysosomálních střádacích chorob na úrovni 
kultivovaných fibroblastů  
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1. INTRODUCTION 
1.1  Mitochondria 
Mitochondria are membrane organelle with wide range of live-important functions for 
eucaryotic cell. They are involved in ATP synthesis, oxidation of fatty acids, they also 
cooperate in apoptotic processes, in calcium homeostasis and they are the center of reactive 
oxygene radicals production. Furthermore, they are involved in porphyrine synthesis and take 
part in amino acid metabolism as well as in metabolisms of large spectrum of xenobiotics. 
The mammalian organism fully depends on the oxidative phosphorylation system 
(OXPHOS) as on the main energy (ATP) producer of the cell. The majority of high energy 
source – ATP used for all active metabolic processes is produced in eucaryotic cells by 
oxidative phosphorylation (OXPHOS) in mitochondria. Disturbances of OXPHOS may be 
caused by mutations in either mitochondrial DNA (mtDNA) or nuclear DNA (nDNA), and 
environmental factors have also been shown to have important effects on OXPHOS. In human 
mitochondria contain a small circular DNA molecule (16 659bp) encoding 11mRNAs and 13 
polypeptides that form, together with nuclear-encoded subunits, five inner-membrane 
OXPHOS complexes. For the translation of these 11 mRNAs (nine monocistronic and two 
bicistronic), mitochondria  use its own separate translational system made of protein 
components encoded exclusively by nuclear genes and RNA components encoded by the 
mitochondrial genome (two ribosomal RNA genes and 22 transfer RNA (tRNA) genes). 
Mitochondrial translation is precisely controlled to meet tissue-specific demands for mtDNA-
encoded structural subunits of the OXPHOS complexes (Antonicka et al., 2006). Although 
the basal components of the mitochondrial expression system are known, the mechanism of 
the system regulation  in response to the metabolic needs of the cell is poorly understood 
(Taanman, 1999). 
There are thousands of mtDNA in each cell, and pathogenic mutations of mtDNA may 
be present in all of mtDNA molecules or only in some of them. As a result, cells and tissues 
may harbor both normal (wild-type) and mutant mtDNA, a situation known as heteroplasmy. 
Therefore, in most cases, the phenotypic manifestation of the genetic defect occurs only when 
a threshold level is exceeded (phenotypic threshold effect). It has been shown that it is 
possible to inhibit considerably the activity of respiratory chain complexes, up to a critical 
value, without affecting the rate of mitochondrial respiration or ATP synthesis (biochemical 
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threshold effect) (Rossignol et al., 2003). The threshold for biochemical expression in 
cultured cells may be up to 95% for tRNA mutations (Bakker et al., 2000) and around 60% 
for mtDNA deletions (Hayashi et al., 1991). The degree of organ dysfunction will also depend 
on tissue’s energy requirement; for instance, brain and muscle are dependent on oxidative 
phosphorylation, and neurological disorders and myopathy are common features of mtDNA 
mutations, whereas skin and other organs are often without pathological phenotype. 
1.2 Mitochondrial structure   
Mitochondria are localized in the cytoplasm of eukaryotic cells and they exist as a 
dynamic network that often changes shape and subcellular distribution. The number and 
morphology of mitochondria within the cell are controlled by precisely regulated rates of 
organelle fusion and fission (Bereiter-Hahn & Voth, 1994). The inner and outer membranes 
create two separate compartments and surround mitochondrial matrix. The inner membrane is 
folded into numerous cristae, which greatly increase its total surface area containing all 
respiratory chain complexes, ATP synthase, and various transport proteins. Mitochondria in 
rat and human hepatocytes as well as in human skin fibroblasts (HSF) grown in culture 
contain tubular cristae observed by high-resolution scanning electron microscopy. The 
fibroblast mitochondria were proved to be long and branched as compared to those in liver 
which were spherical in shape (Lea et al., 1994). 
1.3 Mitochondrial disorders selected as a point of interest 
Mitochondrial disorders caused by mtDNA mutations range from relatively mild, late-
onset manifestation (e.g., sensorineural hearing loss, progressive external ophthalmoplegia, or 
ocular myopathy) to devastating and frequently fatal syndromes, such as MELAS 
(mitochondrial encephalomyopathy with lactic acidosis and stroke-like seizures) or MERRF 
syndrome (myoclonus epilepsy and ragged-red fibers). Furthermore, several lines of indirect 
evidence suggest that mitochondrial dysfunction also may play a role in common disorders 
such as diabetes mellitus or neurodegeneration (Schon & Manfredi, 2003). Despite improved 
characterization of the genetic defects that lead to mitochondrial disorders, the pathogenic 
mechanisms of these diseases are mostly very little understood. An electron microscopic 
observation of mitochondrial ultrastructure together with biochemical and genetic studies 
provide valuable insight into many aspects of mitoc
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We focused on characterization of fibroblast cell lines and tissues harbouring 
mutations in mitochondrial tRNA (3243A>G, prevalent for MELAS syndrome, 8344A>G, 
prevalent for MERRF syndrome, 8363G>A asociated with Leigh syndrome). Mutation in 
mtDNA gene  for ATP6 subunit (8993T>G) in mitochondrial F0F1 ATP synthase has been 
observed only on level of cultured human skin fibroblasts as well as impact of SCO2 mutation 
on selected mitochondrial function.    
1.4 Lysosomal storage diseases 
Lysosomal storage diseases (LSDs) comprise more than 40 genetic disorders with  
cytoplasmatic accumulation of lipids, proteins and/or mucopolysaccharides. Some of LSDs 
are caused by inactivating mutations in lysosomal hydrolytic enzymes or by mutations that 
affect their delivery to lysosome. Other LSDs involve impaired export of hydrolysis products 
(Mach, 2002). 
However, it is not clear if these substrates themselves are the primary mediators of 
toxicity. Indeed, the biological pathways from lysosomal enzyme deficiency to cellular 
dysfunction are still largely unknown. Interestingly, despite the great structural diversity of 
the accumulating substrates in the different LSDs, these disorders share many phenotypic 
similarities suggesting the presence of common pathogenetic mechanisms. 
Postmitotic cells such as neurons and mononuclear phagocytes rich in lysosomes are 
most often affected by the accumulation of undegraded material. Cell death is well 
documented in parts of the brain and in other cells of LSD patients as well as in animal 
models. Although little is known about mechanisms by which death pathways are activated in 
these diseases, while not all cells exhibiting increased storage material are affected by cell 
death.  
1.5 Autophagy 
Lysosomes are essential for maturation and completion of autophagy-initiated protein 
and organelle degradation. Moreover, the accumulation of effete mitochondria has been 
documented in postmitotic cells whose lysosomal function is suppressed or in aging cells with 
lipofuscin accumulation (Terman et al., 2006). 
Most LSDs involve impaired cognitive and motor functions. Loss of neurons is well 
documented in LSD patients and mouse models (Hara et al., 2006) supporting the concept that 
the nervous system is particulary susceptible to altered lysosomal functions. 
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It was suggested that lysosomal deficiencies in LSDs inhibit autophagic maturation, 
and lead to a autophagic stress condition. The resulting accumulation of dysfunctional 
mitochondria showing impaired Ca2+  buffering increases the vulnerability of the cells to pro-
apoptotic signals (Kiselyov et al., 2007; Settembre et al., 2008)  
Not only in LSDs but also in mitochondrial disorders, autophagy process takes part on 
pathogenesis. It was observed in fibroblasts culture harbouring 3243A>G mutation with high 
heteroplasmy loud (Gu et al., 2004) as well as in coenzyme Q deficiency in very recent study 
(Rodriguez-Hernandez et al., 2009). 
Our point of interest is focused on the  group of LSDs previously connected with 
mitochondrial dysfunction on biochemical level (Fabry disease (Lucke et al., 2004), Gaucher 
and Niemann Pick A disease (Strasberg, 1986)) and a group without described mitochondrial 
abnormalities (α-mannosidosis and metachromatic leucodystrophy). 
Changes in autophagy has been also studied in selected group of mitochondrial 
disorders. 
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2. AIMS OF STUDY 
Mitochondrial disorders represent a group of heterogenous diseases with clinical 
onset from newborn age till adulthood, mostly presented with very severe courses. The 
mammalian organism is fully dependent on mitochondrial oxidative phosphorylation 
system as the major energy producer of the cell. Therefore the mitochondrial disorders  
influence mainly high energy demanded tissues such is brain, heart or muscles. Similar 
phenotype is observed in many lysosomal storage disorders as well. 
Despite of the expanding knowledge of molecular basis of mitochondrial and 
lysosomal disorders, it is still difficult to explain exact pathogenesis of the disease as well 
as prognosis for patients. 
 Mitochondrial functions affect more than just  energy production; they contribute 
in initiation of apoptosis, in cellular calcium homeostasis and in production of reactive 
oxygene species. Disturbed mitochondria become a goal of autophagy mediated by the 
lysosomal compartement. 
 
 
Specific aims: 
 
1. To analyze tissue specific impact of selected mtDNA mutations on mitochondrial 
function in autoptic tissues 
 
2. To analyze relations between mitochondrial ultrastructure and a function in selected 
mitochondrial and lysosomal storage disorders on the level of cultured fibroblasts. 
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3. MATERIAL AND METHODS 
3.1 Ethics 
This study was carried out in accordance with the Declaration of Helsinki of the World 
Medical Association, and was approved by the Committee of Medical Ethics of the 1st Faculty 
of Medicine, Charles University and General Faculty Hospital, Prague. Informed parental 
consent, in accordance with the guidelines of the 1st Faculty of Medicine, Charles University, 
was obtained for all autopsies and skin biopsies. 
3.2 Material 
Autoptic tissues with selected mtDNA mutation were available from patients with 
mtDNA mutations: 8363G>A (skeletal muscle, heart muscle, brain tissue, liver tissue), 
3243A>G (skeletal muscle, heart muscle, brain tissue, liver tissue), 8344A>G (skeletal 
muscle). Muscle biopsy was available from patients with mtDNA mutation 8363G>A. 
 
Human skin fibroblasts were derived from patients harbouring:  
• mtDNA mutation: MELAS 3243A>G (2 lines), MERRF 8344A>G (2 lines), 
NARP 8993T>G (1line) and Leigh syndrom 8363G>A  
• LSDs: Fabry disease (5 lines), α -  mannosidosis (3 lines), Niemann - Pick 
disease A (1 line), Gaucher disease (3 lines) and  metachromatic leucodystrofy 
(1 line). 
Up to 20 human fibroblast cell lines without any known mitochondrial or lysosomal 
storage diseases were used as controls.  
3.3 Tissue culture 
The cultures of fibroblasts were established from skin biopsy after informed parental 
consent. Fibroblasts were grown in the Quantum 333 medium (PAA, Austria) at 37°C in 
humid atmosphere containing 5% CO2.  
Inverted microscope Nikon Diaphot 200 was used for the imaging of cellular 
morphology in the phase contrast as well as for the analysis of mitochondrial reticulum 
visualized by MitoTracker green (MTG, Molecular Probes, USA) (1µM).  
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3.4 Activities of respiratory chain complexes  
The activities of the mitochondrial enzymes NADH:CoQ reductase (complex I), 
succinate:CoQ reductase (complex II), cytochrome c oxidase (COX, complex IV), 
NADH:cytochrome c reductase (complex I+III), succinate:cytochrome c reductase (complex 
II+III) and citrate synthase (serving as the control enzyme) were measured 
spectrophotometrically at 37 °C in cultured fibroblasts by modified methods according to 
Rustin et al. The activities of COX were analyzed three times in doublets and they are 
expressed as mean ± SD, other complexes were measured in doublets.  
3.5 Detection of mitochondrial mass, mitochondrial potential and 
production of reactive oxygen species (ROS)  
Human skin fibroblasts were grown in 25 cm2 cultivation flasks until approx. 90% of 
cell confluence was reached. Then, they were exposed to final concentration of 1 µM 
MitoTracker Green (Molecular Probes, USA) for mitochondrial mass measurement. Aliquots 
of cells were incubated with 20 nM TMRM (tetramethylrhodamine methyl ester) for detection 
of mitochondrial potential and 10 mM 2',7'-dichlorodihydro-fluorescein-diacetate (H2DCF-
DA, Molecular Probes, USA) for measurement of ROS in cultivated medium in 37°C in 
humid atmosphere and 5% of CO2 for 30 min. Cells were trypsinized, washed twice with PBS 
and transferred immediately to a tube on ice for flow cytometric analysis.  
3.6 Flow cytometric analysis  
FACS Calibur flow cytometer (BD, San Jose, CA USA) equipped with argon laser 
(488-nm) was used for the flow-cytometric analysis. Forward and side scatters were used to 
establish size gates and exclude debris from the analysis. Intensity of emitted fluorescence 
was detected using bandpass filters: 530 ± 15 nm (FITC) and 585 ± 21 nm (PE/PI), FL1 and 
FL2 channels, respectively. In each measurement, a minimum of 10 000 cells were analyzed. 
Data were acquired and analyzed using the Cell Quest software (BD, San Jose, CA USA). A 
relative change in the mean fluorescence intensity was calculated as the ratio between mean 
fluorescence intensity in the channel of the treated cells and that of the control cells.  
3.7 Ultrastructure analysis  
Cells were fixed based on Luft’s modified method  in PBS containing 2% potassium 
permanganate for 15 min, washed with PBS and dehydrated with an ethanol series. They were 
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then embedded in Durcupan Epon, sectioned by microtome Ultracut Reichert to thickness 
ranging from 600-900Å, stained with lead citrate and uranyl acetate (Luft, 1956). 
Transmission electron microscope (JEOL, JEM-1200EX) was used for imaging.  
3.8 Morphometry  
Modified Nonomura method was used (Nunomura et al., 2001): Micrographs of 
cultivated fibroblasts (derived from four controls cell lines and three patients cell lines) were 
taken at magnification of 5 000x and additionally at 20 000x. Five to ten sections were 
examined in each cell line. Intact mitochondria, swelled mitochondria containing cristae, 
swelled mitochondria without cristae was identified and counted. Percentage rate of each 
morphological group was calculated for each section. Differences between groups were 
evaluated by Mann-Whitney test.  
3.9 Electrophoresis and immunobloting analysis  
Tricine SDS/PAGE was carried out under standard conditions with 12% 
polyacrylamide, 0.1% (w/v) SDS and 5.5 M urea gels. Mitochondrial fractions were 
dissociated in 50 mM Tris/HCl (pH=6.8), 12% (v/v) glycerol, 4% SDS, 2% (v/v) 2-
mercaptoethanol and 0.01% (w/v) Bromophenol Blue for 30 min at 37 °C. Approx. 10 µg of 
protein was loaded for each lane. Proteins were electroblotted from the gels on to 
Immobilon™-P PVDF membranes (Millipore) using semi-dry transfer for 1 h at a constant 
current of 0.8 mA/cm2. Immunodetection using monoclonal antibodies against structural 
subunits of respiratory chain complexes and ATP synthase (Mitosciences, USA) was 
performed according (Stiburek et al., 2005). 
3.10 Fluorescence measurement of cytosolic Ca2+  
The cells grown on glass cover slips were washed in ECS (160mM NaCl, 2,5 mM 
KCl, 1 mM CaCl2, 2 mM MgCl2, 10 mM Hepes-Na, 10 mM glucose; pH=7.4). After the 
washing, the cells were loaded with 1 µM Fura-2 acetoxymethyl ester (Fura-2/AM) for 60 
min at 25 °C, in the dark, rinsed with and kept in ECS for 30 minutes prior to fluorescence 
measurements at 25°C. Ratiometric imaging was performed using Olympus microscope IX 
50, based microspectrofluorimeter (Visitron Systems, Puchheim, Germany), equipped with 
cooled digital CCD camera (MicroMAX RTE/CCD -512EFT, Princeton Instruments, 
Monmouth Junction, NJ, USA). Fluorescence of Fura-2 was excited at wavelengths 340 and 
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380 nm switched by Polychrome II (Till Photonics, Planegg, Germany) illumination device. 
Emitted light at λ>420 nm (filter U-MWU) was recorded every 2 s, integration time for each 
wavelength was 300 ms. Software MetaFluor 7.0 (Universal Imaging Corp. West Chester, 
PA, USA) was used to control synchronization of excitation and data acquisition and for the 
visualization of the relative calcium concentration based on the ratiometric measurement. 
3.11 Immunocytochemistry 
Immunocytochemistry was performed according Capaldi et al. by usage of specific 
primary antibodies against cytochrome c oxidase (subunit II and Va) and porine 
(Mitosciences) and secondary antibodies (Alexa Fluor 488 and 564) (Capaldi et al., 2004). 
3.12 Polarography 
Muscle fibers were separated mechanically and oxygen consumption by saponin-
skinned muscle fibers was determined using multiple substrate inhibitor titration as described 
previously (Wenchich et al., 2003). 
3.13 Semiquantitative RT-PCR 
Total RNA was isolated using the RNeasy kit (Qiagen). First-strand cDNA was 
synthesized using 1 µg of total RNA (DNase-treated) in a 20 µl reverse transcriptase reaction 
mixture and the requested part of cDNA was amplified using specific primers. 
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4. RESULTS AND DISCUSSION 
Ad1: To analyze tissue specific impact of selected mtDNA mutations on 
mitochondrial function in autoptic tissues 
4.1 The impact of mitochondrial tRNA mutations on the amount of 
ATP synthase differs in the brain compared to other tissues  
In the 8363G>A skeletal muscle sample obtained at autopsy, profoundly decreased 
levels of complex I (5% of control) and IV (< 10% of control) were detected. The sample also 
revealed a diminished amount of complex V holoenzyme (35% of control), along with 
accumulated sub-complexes, most likely V* (F1-ATPase with several c-subunits) and F1- 
ATPase.  
A very similar pattern, although less severe, was found in the 8344A>G skeletal 
muscle sample. The amount of complex I was reduced to approximately 25% of control, the 
level of complex IV holoenzyme was < 15% of control, and the holoenzyme level of complex 
V was decreased to 60% of the control value. Immunodetection of complex V further showed 
sub-complexes similar to those observed in the 8363G>A sample. 
In 3243A>G skeletal muscle, relative levels of OXPHOS holoenzymes were normal, 
except for a decrease in the content of complex I to 30% of control and complex IV to 60% of 
control. 
Only the 8363G>A and 3243A>G samples of heart, frontal cortex, and liver tissue 
were available for comparison of the impact of mtDNA mutations on the system of oxidative 
phosphorylation in skeletal muscle and other tissues. The 8363G>A heart sample showed the 
same considerable reduction in complexes I (5% of control) and IV (< 10% of control) 
content as skeletal muscle, but despite the greater reduction of complex V holoenzyme (15% 
of control), there was a significantly lower accumulation of F1-ATPase The 3243A>G heart 
sample had a pronounced reduction of complex I (20% of control), similar to skeletal muscle. 
In the 8363G>A frontal cortex, the assembly of complexes I and IV were less affected 
than in the above-mentioned tissues. The amount of complex I was decreased to 40% of 
control, and the holoenzyme level of complex IV was reduced to 50% of control. Conversely, 
complex V (<20% of control) appeared to be the most severely affected member of the 
OXPHOS system. The decrease was more substantial than in skeletal muscle; nevertheless, no 
detectable sub-complexes could be found. The 3243A>G frontal cortex sample showed a 
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dramatic reduction of complex V to below the detection limits of the method, and of complex 
I to 10% of the control value. Probing of the immunoblots with an anti-COX2 antibody 
showed a reduction of complex IV to 20% of control, as well as the presence of a high 
molecular weight sub-complex. Due to the unexpected OXPHOS deficiency pattern observed 
in brain tissue, particularly in the 3243A>G patient, the immunoblotting was also performed 
on the frontal cortex sample from another 3243A>G patient. In the only available sample with 
a 65% level of heteroplasmy, the immunoblotting analysis revealed normal levels of 
OXPHOS complexes in comparison to control. 
Despite the highest level of heteroplasmy, the 8363G>A liver sample only showed an 
isolated deficiency of complex I (40% of control). Steady-state levels of OXPHOS complexes 
in the 3243A>G liver mitochondria were comparable to control. 
In 8363G>A skeletal muscle, the level of free S1 sub-complex was found to be below 
the detection limit of the method. This probably reflects the limiting character of the COX1 
subunit in the holoenzyme assembly. In 3243A>G frontal cortex, significantly increased 
levels of all known complex IV assembly intermediates were observed, including free 
apoCOX1 (S1 sub-complex), apoCOX2, and apoCOX5A. The high molecular weight band 
just below the COX holoenzyme, which was detected with anti-COX2 antibody, very likely 
represents the S3 assembly intermediate. 
Consistent with immunoblotting results, the spectrophotometry revealed lower activity 
ratios for complex I (I/II and I/CS) in the isolated muscle mitochondria of all three patients, 
and a severe deficiency of complex IV in 8363G>A and 8344A>G isolated muscle 
mitochondria. The COX/SQR (IV/II) and COX/CS (IV/CS) ratios in the 3243A>G patient 
were just below the control range. 
The functional consequences of the 8363G>A mutation in comparison to the 
8344A>G mutation were analysed by high-resolution oxygraphy of the patients´ skeletal 
muscle fibers permeabilized by a low concentration saponin treatment. In both samples, a 
decrease of ADP-stimulated oxygen consumption compared to control fibers was observed 
using pyruvate as a substrate, and an increase was found after succinate addition. A 
pronounced reduction in ADP-stimulated respiration was found after pyruvate (33% of the 
mean control value) as well as after glutamate (32% of the mean control value) additions in 
8363G>A muscle fibers. Indeed, ADP-stimulated respiration after succinate treatment 
increased to 158% of the mean control value. In 8344A>G muscle fibers, ADP-stimulated 
respiration after pyruvate addition was 70% of the mean control value, but after glutamate, it 
was within the reference range. Similarly to 8363G>A muscle fibers, the ADP-stimulated 
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respiration after succinate addition increased to 222% of the mean control value in the 
8344A>G sample. The absolute oxygen consumption after ascorbate + TMPD treatment was, 
in both samples, within control levels; however, normalization of the data to the level of 
respiration after succinate addition revealed decreased ratios after treatment with all of the 
substrates (Fornuskova et al., 2008). 
In the skeletal muscle the lowest level of heteroplasmy but the most severe OXPHOS 
defect suggests a more profound impact of the 8363G>A mutation on the translational system 
than that of the 8344A>G mutation. Concerning the 3243A>G mutation, the relatively 
proportional levels of heteroplasmy in 8344A>G and 3243A>G skeletal muscles, the more 
significant decrease in the content of complex I, the severe decrease in the amount of complex 
IV, and the slightly lower level of complex V all indicate a less pronounced impact of the 
3243A>G mutation on mitochondrial translation in this tissue. However, the different nuclear 
backgrounds (Feuermann et al., 2003), distributions of heteroplasmy levels in cells and 
mitochondria (Durham et al., 2007), and environmental factors (Levy, 2007) which have been 
shown to influence expression of mitochondrial respiratory insufficiency, prevent the 
reduction of these results to any simple quantitative trait. The frequency of UUR (Leu) codons 
in mitochondrially-translated subunits of OXPHOS implies decreased steady-state levels of 
complex I subunits, namely ND6, ND3, ND2 and ND5 (14 – 9 UURs) in 3243A>G 
mitochondria. In 8363G>A and 8344A>G mitochondria, the distribution of AAR (Lys) 
codons anticipates diminished levels of ND5, ND2, ND4 and COX1 (21 - 10 AARs). 
Moreover, all these subunits contain two X/Lys/Lys/X motifs, or one X/Lys/Lys/X and one 
Lys/X/Lys motif (http://www.mitomap.org), which are apparently strong stalling points for 
the ribosome. 
The particular abundance and distribution of codons in mitochondrially-translated 
subunits of respiratory chain complexes appears to be a plausible explanation for the isolated 
defect of complex I in the patient with a mutation in mt-tRNALeu(UUR), along with the 
combined deficiency of complexes I and IV in patients with mutations in mt-tRNALys. 
Furthermore, the complete absence of unassembled apoCOX1 in the skeletal muscle of 
the 8363G>A patient, as revealed by BN/SDS/PAGE immunoblotting, conforms to the 
limiting character of the COX1 subunit in holoenzyme assembly. On the contrary, the 
OXPHOS deficiency patterns found in the frontal cortex mitochondria of the 8363G>A and 
3243A>G patients could suggest, similarly to (stiburek et al., 2005), a specific character for 
brain OXPHOS. First, in both frontal cortex samples, the decrease in the content of complex 
V was more profound than in that of complexes I and IV. Second, despite such a pronounced 
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defect of complex V, no sub-complexes similar to those observed in skeletal muscle and heart 
could be detected, even when the immunoblot exposure was prolonged (data not shown). 
Unfortunately, no 8344A>G frontal cortex specimen was available for the analysis. However, 
a selectively decreased expression of COX2 subunit was previously reported in frontal cortex 
and cerebellum of a MERRF patient (Sparaco et al., 1995). F1-ATPase, which was observed 
in heart, was found along with a sub-complex denoted V* in skeletal muscle. The sub-
complex V* is likely composed of F1-ATPase and several c-FO subunits. These sub-
complexes were described previously in 8993T>G mitochondria (Carrozzo et al., 2006), ρ0 
cells (Carrozzo et al., 2006), and in cells with inhibited mitochondrial translation (Nijtmans et 
al., 1995). The observed steadystate levels of OXPHOS complexes suggest that the brain ATP 
synthase is most sensitive to disturbances of the mitochondrial translational system caused by 
the studied mt-tRNA mutations. Such a tissue-specific impact of mt-tRNA mutations with 
comparable tissue heteroplasmy is likely to result from tissue-specific variations in the nature 
of mitochondria. Indeed, it was shown that the brain, liver and kidney OXPHOS system is 
mainly controlled at the phosphorylation level by ATP synthase and a phosphate carrier, in 
contrast to the muscle and heart, where it is essentially controlled at the level of the 
respiratory chain (Rossignol et al., 2000). On the other hand, instead of diminished energy 
provisions, an insufficient discharge of mitochondrial membrane potential leading to reactive 
oxygen species (ROS) production was proposed as the underlying pathogenic mechanism of 
ATP synthase deficiency (Houstek et al., 2004). Accordingly, the complete lack of complex V 
from 3243A>G frontal cortex may be, apart from the translational defect, responsible for the 
unusual assembly pattern of COX in this sample. Indeed, it was shown in yeast that (i) cells 
deficient in ATP synthase have a severe reduction of COX holoenzyme  (Rak et al., 2007) and 
(ii) no decrease in COX synthesis is observed in uncoupled ATP synthase mutants, where the 
maintenance of mitochondrial potential is severely compromised by a massive proton leak 
through the FO sector (Houstek et al., 2004). Although the COX1 subunit was shown to be a 
key regulatory target for COX reduction in yeast cells (Rak et al., 2007) some other 
mechanism is likely to be involved in the hindered assembly of COX in the 3243A>G frontal 
cortex mitochondria, since this sample had high accumulated levels of all three 
mitochondrially encoded subunits, either free or partially assembled. 
Although it is necessary to analyze considerably more samples with high levels of 
heteroplasmy (such samples are difficult to obtain), these data show new effects of mt tRNA 
mutations on the brain which differ substantially from those described for skeletal muscle, 
heart, and liver tissues. 
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Ad 2: to analyze connection between mitochondrial ultrastructure and 
function in selected mitochondrial and lysosomal storage disorders 
on level of cultured fibroblasts. 
4.2 Mitochondrial ultrastructure and function in selected 
mitochondrial and lysosomal  storage disorders on level of cultivated 
fibroblasts  
Ultrastructural analysis of cultivated fibroblasts of our patients with mtDNA point 
mutations revealed heterogeneous mixture of variously changed mitochondria with unusual, 
rare cristae. This heterogenity in size and shapes of mitochondria in a single cell suggests the 
presence of different levels of heteroplasmy within the individual cell (intracellular 
heteroplasmy, even further intramitochondrial: a single mitochondrion can harbor several 
copies of mtDNA, in that case both: normal and mutant mtDNAs). Intercellular heterogenity 
in mitochondrial morphology of heteroplasmic cells carrying the mtDNA mutation 3243A>G 
were described by Bakker et al. (Baker et al., 2001). They observed that the number of 
defective cells increased with increasing mutation load. The cristae of our patients' 
mitochondria with mtDNA mutation 3243A>G, 8344A>G, and 8993T>G were poorly 
developed, occurred sparsely or were absent. The control samples' mitochondria had 
numerous long cristae, often like septa, and filamentous morphologies of mitochondria were 
far more prevalent than the oval ones (Brantova et al., 2006) (Fig.1) 
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Fig.1: Effete mitochondria in cultivated human skin fibroblasts derived from patients with 
mitochondrial disease (A-C) and derived from control cell line (D). 
 
Very similar mitochondrial abnormalities to mitochondrial disorders harbouring cells 
were observed in all examined LSDs cell lines. In addition, dilated endoplasmatic reticulum 
(ER) was obvious in fibroblasts derived form patients with α-mannosidosis. 
Moreover, in both – mitochondrial disorders and LSDs cell lines, mitochondria with 
damaged cristae had a swollen and bubble-like structure, a diagnostic marker related with 
injured or missing cristae. Similar observations of the mitochondrial morphological changes 
in fibroblasts were also described by other autors (Procaccio et al., 1999). 
The correlation of the ultrastructural abnormalities of cristae with the impact on their 
function is based on location of oxidative phosphorylation. Gilkerson et al. (Gilkerson et al., 
2003) assumes that around 94% of both respiratory chain complex III  and the ATP synthase 
are located in the cristal membrane, and only around 6% of either is in the inner boundary 
membrane; both complexes exist at a 2.2- to 2.6-fold higher concentration in the cristal 
membrane. Further, related data showed the ATP synthase to be involved in the process of 
generating mitochondrial cristae morphology (Paumard et al., 2002). Convincing argument 
for topology of the mitochondrial inner membrane and bioenergetic implications brings 
electron tomography together with computer modeling studies using the Virtual Cell program. 
The shape of the inner membrane can influence OXPHOS function. Simulation indicates that 
narrow cristae junctions restrict diffusion between intracristal and external compartments, 
causing depletion of ADP and decreased ATP output inside the cristae (Mannella et al., 2001). 
A B 
C D 
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All this evidence may explain how mitochondrial morphology, function, and bioenergetics are 
linked together. Nevertheless, the primary cause of all documented pathology lies in genetic 
defects proved by mtDNA analysis. The onset and severity of clinical manifestations depend 
on a delicate balance between the energy supply (determined in part by the proportion of 
mutant and normal mtDNA) and oxidative demands of different organ systems. 
4.2.1 Activities of respiratory chain enzymes 
Fibroblasts cell lines harbouring mutations in mtDNA did not reveal any profound 
changes in activities of respiratory chain complexes compare to the controls except line with 
mtDNA mutation 8363G>A, where the activity of cytochrome c oxidase (COX) was under 
detection limit of used methods. Boundary activity of COX was detected in one patient with 
high heteroplasmy loud of mtDNA mutation 3243A>G.     
Majority of examined cell lines derived from patients with LSDs revealed disbalance 
in activities of respiratory chain, some of them with tendency to increased activities of COX 
or complex I. The most profound changes were detected in cell cultures derived from patients 
with α-mannosidosis, where the activity of respiratory chain complexes and control enzyme 
citrate synthase revealed significantly increased activity of complex IV in all studied cell lines 
compare to controls (p=0,05), the ratio between complex IV and CS was increased as well. In 
addition, the activity of complex I or complex I+III was at the upper border of the reference 
range or increased compare to the controls. It resulted in increased ratio between complex I or 
I+III and CS in each studied fibroblasts. The activities of respiratory chain complex II were in 
reference range and the activities of CS were slightly decreased in one of patients. (Brantova 
et al., 2009). 
Mild decreased of COX activity was observed in cell lines derived from patients with  
Gaucher disease and metachromatic leucodystrophy, however, after normalization to citrate 
synthase, the values reached reference range. 
Contrary to our results, declined activities of all respiratory complexes except complex 
II were described in cultivated fibroblasts from patients with Fabry disease (Lucke et al., 
2004). Therefore we examined influence of elevated level of storage material 
(globotriosylceramide, GB3) added to cultivated medium on respiratory chain and we did not 
detect any declination in enzyme activities. There is a possibility, that increased load  GB3 
was not sufficient to cross a treshold level to reach the described phenotype. 
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4.3 Mitochondrial mass and superoxide production 
Cultivated fibroblasts with mtDNA mutation 3243A>G a 8344A>G revealed tendency 
to increase mitochondrial mass as well as level of mitochondrial superoxide contrary to 
controls. Although previous study did not detect any changes in mitochondrial mass (James et 
al., 1996), our observation is in accordance with tight connection between elevated oxidative 
stress and mitochondrial mass (Lee et al., 2000). 
Elevating of oxidative stress in fibroblasts from patients with SCO2 and NARP 
syndrome, we did not observe increased mitochondrial mass. Explanation  may be due to 
elevated rate of autophagy. 
Production of mitochondrial superoxides was detected in all fibroblasts cell lines 
derived from patients with LSDs except Fabry disease. Significant change in mitochondrial 
mass was observed only in cultures derived from patients with α-mannosidosis, where we 
observed declination in mitochondrial mass. 
Elevated level of  mitochondrial superoxide production could advert to accumulation 
of effete mitochondria in cells, which is in accordance with elelectron microscopy 
observation. 
High level of oxidative stress was previously observed in neurons derived from 
patients with Gaucher disease (Deganuto et al., 2007). In our study, we focused on 
mitochondria and we could complete the information about mitochondrial participation on 
oxidative stress in LSDs. 
Contrary to our results, high level of reactive oxygene species in cultivated endothelial 
cells obtained from patients with Fabry disease was detected, however only when the cells 
were cultured in medium supplement with patients serum (James et al., 1996). It could be one 
of the reasons for normal findings in our fibroblasts cell lines. Another explenation may be 
non-mitochondrial origin of oxidative stress in cells.  
4.3.1 Mitochondrial calcium homeostasis in HSF derived from 
selected mitochondrial and lysosomal storage disorders  
The amount of calcium retained in mitochondria was monitored by usage of  
cytoplasmatic probe Fura 2AM, further Bradykinine and FFCP.   
During release of calcium from ER after Bradykinin treatment, part of it is absorbed 
by mitochondria. FCCP releases mitochondrial calcium to cytoplasm.  
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Our study showed profound changes in mitochondrial calcium amount in cells derived 
from patients with MELAS, MERRF and SCO2 syndromes as well as in fibroblasts from 
Gaucher and Niemann Pick A disease. Only mild declination in mitochondrial calcium 
amount was detected in cell culture from patients with NARP syndrome; fibroblasts with α - 
mannosidosis and Fabry disease remained in normal. 
Disturbed calcium homeostasis was previously documented in large scale of 
mitochondrial disorders. Rizzuto et al. described different answers to stimulation of calcium 
metabolism in fibroblasts harbouring mtDNA mutations 8356T>C and 8993T>G with impact 
on cell ATP production (Brini et al., 1999). Elevated level of cytoplasmatic calcium was 
observed in mtDNA mutations 3243A>G a 8344A>G. It could be related to disturbed 
mitochondrial ability to buffer cellular calcium (Moudy et al., 1995). 
Pathology of Gaucher (Lloyd-Evans et al., 2003) and Niemann Pick A disease 
(Ginzburg & Futerman, 2005) is connected to impaired calcium homeostasis. However 
calcium disbalance has never been connected to disturbance of mitochondria. 
Elevated calcium concentration in cell cytoplasm implicates higher oxidative stress 
and higher intramitochondrial amount of calcium activates respiratory chain. It is in 
concordance with our results. 
4.3.2 Autophagy 
Autophagy has been monitored during cell starvation as the presence of LC3I and LC3 
II after immunoblot detection.  
Tendency to elevated autophagy rate was observed in fibroblasts derived from patients 
with MERRF and SCO2 syndrome. 
Effect of autophagy on elimination of effete mitochondria was documented previosly 
in cell culture derived from patients with MELAS syndrom  (Gu et al., 2004) as well as in 
coenzyme Q deficiency (Rodriguez- Hernandes et al., 2009).  
No changes of autophagy rate was observed in fibroblast derived from selected LSDs, 
except Fabry disease after higher cultivation in medium with storage material, GB3. 
Mentioned cell line revealed blocking of autophagy on protein level. It was confirmed on 
transcriptional level by  RT-PCR. 
Based on our results, we conclude effect of autophagy on mitochondrial disorders and 
possible mechanisms of elimination of ROS production in condition of elevated autophagy. 
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The block of autophagy observed in one patients with increased intracellular storage could be 
more profound in other energy demanded disorders. 
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5. CONCLUSION 
The results of our study improved the knowledge of exact pathogenesis in 
mitochondrial disorders and in LSDs disorders with secondary disturbed mitochondrial 
functions, especially in: 
 
 
• better understanding of tissue specific impact of selected mtDNA mutations on 
mitochondrial function. 
Obtained data from autoptic tissues revealed new effects of mt tRNA mutations on 
the brain which differ substantially from those described for skeletal muscle, heart, 
and liver tissues. 
 
• better understanding of relation between mitochondrial ultrastructure and function in 
selected mitochondrial and lysosomal storage disorders on the level of cultured 
fibroblasts. 
Based on our results, we conclude primary effect of mutations connected with 
mitochondria as well as secondary influence of LSDs on mitochondrial 
ultrastructure, respiratory chain activities, mitochondrial superoxide production, 
calcium disbalance and autophagy homeostasis.  
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